Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec 8;14(24):6040.
doi: 10.3390/cancers14246040.

Combination Immunotherapy in Prostate Cancer

Constantin N Baxevanis  1 , Maria Goulielmaki  1 , Angelos D Gritzapis  1 , Sotirios P Fortis  1
Affiliations
Editorial

Combination Immunotherapy in Prostate Cancer

Constantin N Baxevanis et al. Cancers (Basel). .

Abstract

During the last decade, there has been significant progress in the field of prostate cancer therapeutic treatments based on androgen receptor-axis-targeted therapies, which resulted in improved clinical outcomes [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Mukherjee A.G., Wanjari U.R., Prabakaran D.S., Ganesan R., Renu K., Dey A., Vellingiri B., Kandasamy S., Ramesh T., Gopalakrishnan A.V. The Cellular and Molecular Immunotherapy in Prostate Cancer. Vaccines. 2022;10:1370. doi: 10.3390/vaccines10081370. - DOI - PMC - PubMed
    1. Bilusic M., Madan R.A., Gulley J.L. Immunotherapy of Prostate Cancer: Facts and Hopes. Clin. Cancer Res. 2017;23:6764–6770. doi: 10.1158/1078-0432.CCR-17-0019. - DOI - PMC - PubMed
    1. Markowski M.C., Shenderov E., Eisenberger M.A., Kachhap S., Pardoll D.M., Denmeade S.R., Antonarakis E.S. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate. 2020;80:407–411. doi: 10.1002/pros.23955. - DOI - PMC - PubMed
    1. Baxevanis C.N., Fortis S.P., Ardavanis A., Perez S.A. Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. Cancers. 2020;12:2908. doi: 10.3390/cancers12102908. - DOI - PMC - PubMed
    1. van den Eertwegh A.J., Versluis J., van den Berg H.P., Santegoets S.J., van Moorselaar R.J., van der Sluis T.M., Gall H.E., Harding T.C., Jooss K., Lowy I., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–517. doi: 10.1016/S1470-2045(12)70007-4. - DOI - PubMed

Publication types

LinkOut - more resources